Siemens Healthineers: EPS Misses Expectations in FY 2024
Monday, Nov 11, 2024 3:34 am ET
4min read Siemens Healthineers, a leading medical technology company, recently announced its fiscal year 2024 earnings, which fell short of analysts' expectations. Despite a strong fourth quarter, the company's earnings per share (EPS) missed targets, primarily due to slower growth in China and the impact of the rapid COVID-19 antigen-test business's end. This article delves into the factors contributing to the EPS miss and assesses the company's growth prospects.
Siemens Healthineers' fiscal year 2024 earnings saw an adjusted basic EPS of €2.23, below analysts' expectations. This miss was primarily driven by slower growth in China, which declined by midsingle digits. However, the company's growth in other geographies remained robust, with comparable revenue growth of 5.6% and an overall adjusted EBIT margin of 17.7%. Key factors driving growth in other regions include strong demand for imaging, Varian, and advanced therapies segments.
The company's Imaging Division, typically a key growth driver, grew less strongly than expected in the third quarter. The division, which accounts for around 53% of sales, grew by 4.5% to 5.5% instead of the projected 6% to 8%. This slower growth, coupled with a decline in China's market, impacted overall revenue growth and earnings.
Despite the EPS miss, Siemens Healthineers' growth in other geographies is sustainable, supported by favorable market trends and a strong pipeline of innovative products. The company's solid financials, with free cash flow of around €2.1 billion, and a proposed dividend of €0.95 per share, unchanged from the prior year, indicate the company's financial stability.
Siemens Healthineers' dividend policy reflects the company's commitment to returning capital to shareholders while maintaining financial stability. In fiscal year 2024, the company proposed a dividend of €0.95 per share, unchanged from the prior year. This decision demonstrates Siemens Healthineers' confidence in its long-term growth prospects and ability to generate cash flow, despite missing EPS expectations in the fourth quarter.
The company's fiscal year 2025 outlook, with expected comparable revenue growth of 5% to 6% and adjusted basic EPS between €2.35 and €2.50, suggests a continuation of its growth trajectory despite market weakness in China. This outlook may reassure investors, as it aligns with the company's long-term strategy and indicates resilience in the face of short-term challenges.
In conclusion, Siemens Healthineers' EPS miss in fiscal year 2024 was primarily driven by slower growth in China and the impact of the rapid COVID-19 antigen-test business's end. Despite this setback, the company's growth in other geographies remains robust, supported by strong fundamentals and a favorable outlook for fiscal year 2025. Investors should consider the company's long-term growth prospects and financial stability when evaluating its investment potential.
Siemens Healthineers' fiscal year 2024 earnings saw an adjusted basic EPS of €2.23, below analysts' expectations. This miss was primarily driven by slower growth in China, which declined by midsingle digits. However, the company's growth in other geographies remained robust, with comparable revenue growth of 5.6% and an overall adjusted EBIT margin of 17.7%. Key factors driving growth in other regions include strong demand for imaging, Varian, and advanced therapies segments.
The company's Imaging Division, typically a key growth driver, grew less strongly than expected in the third quarter. The division, which accounts for around 53% of sales, grew by 4.5% to 5.5% instead of the projected 6% to 8%. This slower growth, coupled with a decline in China's market, impacted overall revenue growth and earnings.
Despite the EPS miss, Siemens Healthineers' growth in other geographies is sustainable, supported by favorable market trends and a strong pipeline of innovative products. The company's solid financials, with free cash flow of around €2.1 billion, and a proposed dividend of €0.95 per share, unchanged from the prior year, indicate the company's financial stability.
Siemens Healthineers' dividend policy reflects the company's commitment to returning capital to shareholders while maintaining financial stability. In fiscal year 2024, the company proposed a dividend of €0.95 per share, unchanged from the prior year. This decision demonstrates Siemens Healthineers' confidence in its long-term growth prospects and ability to generate cash flow, despite missing EPS expectations in the fourth quarter.
The company's fiscal year 2025 outlook, with expected comparable revenue growth of 5% to 6% and adjusted basic EPS between €2.35 and €2.50, suggests a continuation of its growth trajectory despite market weakness in China. This outlook may reassure investors, as it aligns with the company's long-term strategy and indicates resilience in the face of short-term challenges.
In conclusion, Siemens Healthineers' EPS miss in fiscal year 2024 was primarily driven by slower growth in China and the impact of the rapid COVID-19 antigen-test business's end. Despite this setback, the company's growth in other geographies remains robust, supported by strong fundamentals and a favorable outlook for fiscal year 2025. Investors should consider the company's long-term growth prospects and financial stability when evaluating its investment potential.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.